EMBCEmbecta Corp.
Is the price fair?
Undemanding: modest expectations priced in and cheap against its own history.
Priced for a decline (~−29% a year). Little growth is priced in even as revenue fell 3% a year over three years, potential value, or a value trap.
Cheap vs its own history: P/E 3.9 vs a 9.6 median over 17 quarters (−59% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What EMBC's price assumes
Embecta Corp. trades at 3.92× earnings against 39.2× for the median Medical Instruments & Supplies name, cheaper than its own group.
Trailing P/E · Medical Instruments & Supplies median 39.2 · cheaper than the typical name in its group
- Free cash flow yield
- 48%
Free cash flow yield · Medical Instruments & Supplies median 3.4%
- Growth the price implies
- −29%
Growth the price implies · The price pays for −29% free cash flow growth a year for a decade; the business has delivered +33% a year over the last three.
Details›
- Healthcare median P/E509 names
- 26.0
- Medical Instruments & Supplies median P/E33 names
- 39.2
- Free cash flow, trailing twelve months
- $165M
- Market capitalisation
- $342M
- 3-year revenue growth
- −2.9%
- 3-year free cash flow growth
- +33%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 3.92× today against a 9.58× median |
| 52-week range | $2.89 – $14.20 |
| Today | $3.35 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Instruments & Supplies
Ranks #3 of 21 by RyuScore